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Venous thromboembolism (VTE), a disease entity comprising deep vein thrombosis (DVT)
and pulmonary embolism (PE), is a frequent and potentially life-threatening event. To date
different agents are available for the effective treatment of acute VTE and the prevention
of recurrence. For several years, the standard of care was the subcutaneous application
of a low molecular weight heparin (LMWH) or fondaparinux, followed by a vitamin K
antagonist (VKA). The so-called direct oral anticoagulants (DOAC) were introduced rather
recently in clinical practice for the treatment of VTE. DOAC seem to have a favorable risk-
benefit profile compared to VKA. Moreover, DOAC significantly simplify VTE treatment
because they are administered in fixed doses and no routine monitoring is needed.
Patients with objectively diagnosed DVT or PE should receive therapeutic anticoagulation
for a minimum of 3months. Whether a patient ought to receive extended treatment needs
to be evaluated on an individual basis, depending mainly on risk factors determined by
characteristics of the thrombotic event and patient-related factors. In specific patient
groups (e.g., pregnant women, cancer patients, and elderly patients), treatment of VTE
is more challenging than that in the general population and additional issues need to be
considered in those patients. The aim of this review is to give an overview of the currently
available treatment modalities of acute VTE and secondary prophylaxis. In particular,
specific aspects regarding the initiation of VTE treatment, duration of anticoagulation,
and specific patient groups will be discussed.
Keywords: venous thromboembolism, deep vein thrombosis, pulmonary embolism, anticoagulation, secondary
prevention
Introduction
Venous thromboembolism (VTE) is the third most frequent cardiovascular disease after myocardial
infarction (1, 2) and stroke (3).The estimated incidence rate of VTE is around one case per 1000
person-years (4, 5). The most frequent site of VTE is deep vein thrombosis (DVT) of the legs (6).
A potentially life-threatening complication ofDVT is pulmonary embolism (PE), which occurs upon
embolization of a thrombus into the pulmonary arteries. The term VTE has been coined for both,
DVT and PE, and will be used in this review.
For several years, the standard of care treatment of acute VTE was the subcutaneous application
of low molecular weight heparin (LMWH) or fondaparinux, followed in time by the oral intake of
a vitamin K antagonist (VKA) (7, 8).This regimen is highly effective for the prevention of recurrent
VTE (9). However, the treatment with a VKA requires close monitoring due to a narrow therapeutic
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range and a relatively high rate of bleeding complications. In
addition, the acute treatment of VTE requires parenteral anticoag-
ulation with subcutaneous injections of LMWH or fondaparinux
due to the delayed onset of action of VKA.
Recently a new class of agents, the so-called direct oral anti-
coagulants (DOAC), was introduced into clinical practice for
acute and long-term treatment of VTE. Large clinical trials had
shown that DOAC are effective and safe in the treatment of
VTE, compared to the standard regimen with LMWH/VKA (10–
13). Three DOAC, rivaroxaban, apixaban, and dabigatran, have
already received approval for the treatment ofVTEby the food and
drug administration (FDA) and the European medicines agency
(EMA). Edoxaban has been approved in the USA and Japan and
is currently awaiting approval in Europe. DOAC significantly
simplify the treatment of VTE because they are given in a fixed
dose and no routine monitoring is needed. Moreover, in meta-
analyses DOAC were associated with a significantly lower risk of
bleeding complications (14, 15).
In this review, we give an overview of the present state-of-the-
art for the treatment of DVT and PE. Furthermore, we mean to
provide guidance for clinical decision-making with regard to the
various available treatment modalities for specific patient groups
and their very particular requirements.
Considerations Before Initiation of
Treatment
Hemodynamically Unstable Pulmonary Embolism
Patients with suspected PE who are hemodynamically unstable
and present with shock or hypotension are at high risk of short-
term mortality (16). If PE is confirmed, such patients should be
considered for thrombolysis, and in exceptional cases for surgical
or catheter embolectomy (e.g., when they are not at high risk
of bleeding) (16, 17). Moreover, in patients with hypotension
or shock unfractioned heparin (UFH) should be used for initial
anticoagulation instead of LMWH, fondaparinux or a DOAC
according to the current guidelines of the European society of
cardiology (ESC) (18).
The pulmonary embolism severity index (PESI) score and its
simplified version can be used for discriminating between patients
who need to be hospitalized or could potentially be treated in the
ambulatory setting (19–22).
High Bleeding Risk
According to the current American college of chest physicians
(ACCP) guidelines, in patients with acute proximal DVT or PE
an inferior vena cava filter might be placed, if anticoagulation
is not possible due to an exceedingly high bleeding risk (23).
However, the ACCP guidelines do not go into more detail and
“bleeding risk” is not clearly defined. Estimation of the bleeding
risk can be guided by a prospectively validated clinical score, such
as the RIETE score (24) and the HEMORR2HAGES score (25).
The usefulness and applicability of these scores for routine clinical
practice yet remains to be established.
Regarding permanent vena cava filters it is important to con-
sider that they are associated with a number of long-term com-
plications like filter thrombosis and filter migration. Temporary
filters must be removed within a few days, while retrievable filters
can be left in place for longer periods (25).
Impaired Renal Function
Lowmolecular weight heparin and fondaparinux aremainly elim-
inated by the kidneys while UFH is mainly eliminated by the
reticuloendothelial system and VKA by CYP2C9 and the vita-
min K epoxide reductase of the liver (26). In patients with a
creatinine clearance of<30mL/min, caution is indicated because
LMWH and particularly fondaparinux are likely to accumulate,
thus eventually resulting in over-anticoagulation. LMWH and
fondaparinux can be monitored by measuring the peak anti-
factor Xa activity (4 h after administration). However, therapeutic
ranges are not clearly defined. For LMWH with a twice-daily
injection schedule, a peak anti-factor Xa activity of 0.6–1.0 IU/mL
is currently suggested as effective therapeutic anticoagulation (27,
28). The therapeutic range for once daily dosing is less clear and
suggested to be 1.0–2.0 IU/mL (28).
Renal function is also an important factor, if anticoagulation
with a DOAC is considered. In the Hokusai-VTE trial that inves-
tigated edoxaban, a reduced dose (30mg instead of 60mg once
daily) was given to patients with a glomerular filtration rate (GFR)
between 30 and 50mg/dL, which was shown to be safe, and those
with a GFR below 30mg/dL were excluded (11). In the large
controlled trials that have led to the approval of rivaroxaban,
dabigatran, and apixaban, patients with a GFR below 30mg/dL
(rivaroxaban and dabigatran) or with a GFR below 25mg/dL
(apixaban) were excluded (10, 29–31). For rivaroxaban a dose
reduction rule is given in the package insert for patients with a
GFR between 15 and 30mg/dL. However, we do not recommend
the use of any DOAC in patients with a GFR below 30mg/dL (or
below 25mg/dL for apixaban) because of the lack of clinical data.
Treatment Modalities for Acute Deep Vein
Thrombosis and Pulmonary Embolism
A summary of the design and characteristics of the studies is
presented in Table 1. A schematic overview of the inhibitory
effects of different anticoagulants in the coagulation cascade is
given in Figure 1. For detailed information on contraindica-
tions and drug interactions, the reader is referred to the package
insert/prescribing information of the respective agent.
LMWH or Fondaparinux Followed by VKA
The standard treatment of acute DVT and PE for many years has
been the initial administration of a LMWH or fondaparinux at
a therapeutic dose, followed by the (initially overlapping) oral
intake of a VKA. The parenteral drug can be stopped when an
international normalized ratio (INR) of 2.0 is reached on two
successive days. Parenteral anticoagulation should be performed
for at least 5 days.
Vitamin K antagonists are highly effective in the prevention of
recurrent VTE with a relative risk reduction of ~85% compared
to placebo (9). However, it is a drawback that the intake of VKA
needs to be closelymonitored due to the narrow therapeutic range
and that even in specialized centers only about 60% of the INR
values are within the therapeutic range (32) (Table 1). Moreover,
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TABLE 1 | Characteristics of the studies that investigated the efficacy of DOAC compared to VKA for treatment of VTE.
Study Einstein DVT+PE AMPLIFY RE-COVER I+ II Hokusai-VTE
Drug Rivaroxaban Apixaban Dabigatran Edoxaban
Total number of patients 8246 5365 5107 8240
Target Factor Xa-inhibition Factor Xa-inhibition Thrombin-inhibition Factor Xa-inhibition
Primary efficacy outcome Recurrent venous thromboembolism
Principal safety outcome Major- or clinically relevant non-major bleeding
Study design Open-label, randomized
non-inferiority trial
Randomized, double-blind
trial
Randomized, double-blind,
non-inferiority trial
Randomized, double-blind,
non-inferiority trial
Time INR in therapeutic
rangea
57.7% 61% 60% 63.5%
Regimen/dose (mg) 15mg twice daily for the first
3weeks followed by 20mg
once daily
10mg twice daily for the first
7 days, followed by 5mg
twice daily
Initial treatment (at least
5 days) with parenteral
anticoagulant, followed by
150mg twice daily
Initial treatment (at least
5 days) with parenteral
anticoagulant, followed by
60mg once daily
Treatment duration 3-, 6-, and 12months 6months 6months 3–12months duration
determined by the treating
physician based on patient’s
clinical features and
preference
Dose adjustment No No No Yesb
Dose reduction criteria Not assessed Not assessed Not assessed 30mg once daily in patients
with a CrCl 30–50mL/min,
body weight 60 kg or
concomitant treatment with
potent P-glycoprotein
inhibitor
Most important exclusion
criteria as listed in the
publications (full list of
exclusion criteria provided
in the study protocols)
Another indication for VKA,
CrCl <30mL/min, liver
disease, bacterial
endocarditis,
contraindications for
anticoagulant treatment,
systolic blood pressure
>180mmHg or diastolic
blood pressure >110,
childbearing potential without
proper contraceptive
measures, pregnancy or
breast feeding, concomitant
use of strong cytochrome
P450 3A4 inhibitors, bacterial
endocarditis
Contraindications to heparin
or warfarin, CrCl <25mL/min
or creatinine level
>2.5mg/dL, liver disease,
cancer with long-term
treatment with LMWH,
provoked DVT or PE in the
absence of a persistent risk
factor for recurrence, another
indication for long-term
anticoagulation therapy, dual
antiplatelet therapy, aspirin at
a dose of more than 165mg
daily, hemoglobin <9mg/dL,
platelet count
<100.000/mm3
Another indication for a VKA
or heparin, CrCl <30mL/min,
liver disease, PE with
hemodynamic instability or
requiring thrombolytic
therapy, recent unstable
cardiovascular disease, high
risk of bleeding, liver disease,
contraindication to heparin,
pregnancy or risk of
becoming pregnant long-term
antiplatelet therapy (aspirin
100mg accepted), life
expectancy less than
6months
Another indication for VKA,
CrCl <30mL/min,
contraindications to heparin
or warfarin, cancer with
long-term treatment with
LMWH, treatment with aspirin
at a dose of more than
100mg daily or dual
antiplatelet therapy
aTarget INR (vitamin K antagonist) in all studies: 2.0–3.0.
CrCL, creatinine clearance; VKA, vitamin K antagonist; LMWH, low molecular weight heparin; DVT, deep vein thrombosis; PE, pulmonary embolism.
b In the Hokusai-VTE study, 17.8% of patients received the adjusted dose of edoxaban (30mg once daily) at randomization.
a relatively high risk of intracranial bleeding (1.1 per 100 patient-
years) and a case-fatality rate of major bleeding of 13.4% were
reported in a meta-analysis by Linkins et al. (30).
Direct Oral Anticoagulants
Rivaroxaban is a direct factor Xa inhibitor and the first DOAC that
was approved in 2012 for the treatment of VTE. The initial dose
of rivaroxaban for the treatment of acute VTE is 15mg twice daily
for 3weeks followed by 20mg once daily for at least 3months. This
fixed dose treatment regimen was chosen for all included patients
irrespective of their body weight or age. The efficacy of rivarox-
aban in the treatment of acute DVT and PE was demonstrated
in two large open-label trials (Einstein DVT and Einstein PE)
(30, 31). These studies compared rivaroxaban with the standard
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FIGURE 1 | Schematic overview of the inhibitory effects of different
anticoagulants in the blood coagulation cascade. Abbreviations: AT III,
antithrombin III; LMWH, low molecular weight heparin, PL, phospholipid; TF,
tissue factor; VKA, vitamin K antagonists, UFH, unfractioned heparin; F###:
blood coagulation factor denoted in Roman numerals. Active forms are
denoted by a small “a” added to the Roman number, red lines: inhibition by
anticoagulants, dotted lines: positive feedback loops by thrombin. VKA inhibit
the synthesis of the coagulation factors II, VII, IX, and X by acting as a
competitive inhibitor of the enzyme vitamin K epoxide reductase. LMWH and
UFH bind to AT thereby increasing the ability of ATIII to inhibit thrombin up to
1000-fold. LMWH and UFH also directly inhibit FXa. UFH rather target AT III
and LMWH rather target FXa. Fondaparinux, rivaroxaban, apixaban, and
edoxaban directly inhibit FXa. Dabigatran directly inhibits thrombin.
of care treatment (LMWH followed by VKA) and were designed
as non-inferiority studies. In both studies rivaroxaban proved
as effective as LMWH followed by VKA with similar bleeding
rates. In the Einstein-Extension study (published together with
the Einstein PE study), the extended anticoagulant treatment for
12months with 20mg rivaroxaban once daily was tested in com-
parison to placebo. Rivaroxaban substantially reduced the rate
of long-term VTE at the cost of a moderately increased risk of
bleeding.
Apixaban, also a direct factor Xa inhibitor, was approved
in 2014 for the treatment of VTE. The initial dose of apixa-
ban is 10mg twice daily for 7 days followed by apixaban 5mg
twice daily for at least 3months. Apixaban was tested in the
AMPLIFY study, a double-dummy double-blind trail, and was
non-inferior compared to standard treatment (12). Major bleed-
ing occurred less frequently under the treatment with apixa-
ban. In the AMPLIFY Extension study patients were random-
ized into two different doses of apixaban (5 or 2.5mg twice
daily) or placebo for testing VTE recurrence during 12months
of extended treatment. Both treatment doses of apixaban sim-
ilarly reduced the risk of recurrent VTE without an increased
risk of major bleeding (29). Based on these findings, patients
designated for infinite anticoagulation should be given apixaban
5mg twice daily for 6months followed by apixaban 2.5mg twice
daily.
Dabigatran is a direct thrombin inhibitor that was also
approved in 2014 for the treatment of VTE. Two double-blind,
double-dummy studies (RE-COVER and RE-COVER II) found
that Dabigatran was non-inferior compared to standard treatment
and no differences with regard to major bleeding episodes were
found. Initial treatment is started with a LMWH at a therapeu-
tic dose for 5–7 days followed by dabigatran 150mg twice daily
for at least 3months. According to the prescribing information
individuals older than 79 years should get dabigatran at a reduced
dose. However, this recommendation is not based on clinical
data, as no dose adjustment was performed in the RE-COVER
studies.
The direct factor Xa inhibitor edoxaban has been approved in
the USA and Japan and is currently under regulatory review in
Europe. Edoxaban was investigated in the Hokusai-VTE study,
a double-blind, double-dummy study that compared edoxaban
to standard treatment (11). Patients initially received LMWH
for 5 days followed by edoxaban 60mg once daily, which was
reduced to edoxaban 30mg once daily in patients with a creatinine
clearance of 30–50mL/min or a body weight below 60 kg. Edox-
aban was administered for a flexible duration of 3–12months,
and a 12-month follow-up was performed in all patients. Edox-
aban was non-inferior compared to standard treatment and less
clinically relevant non-major bleedings occurred, which was the
main safety outcome. In a sub-group analysis, a favorable efficacy
outcome was noted in patients with severe PE who presented with
evidence of right ventricular dysfunction (defined as NT pro-
BNP 500 pg/mL) in the edoxaban-treatment arm compared to
warfarin.
Duration of Anticoagulation
Venous thromboembolism is a disease that may often recur, with
a 5-year recurrence risk of up to 20–25%. Extended thrombopro-
phylaxis is effective in preventing recurrence of VTE, but it is also
associated with a substantially increased risk of major bleeding.
Whether a patient should receive extended thromboprophylaxis
thus needs to be evaluated on an individual basis, mainly depend-
ing on risk factors determined by characteristics of the thrombotic
event and by patient-related factors.
The ACCP in its most current guidelines from 2012 rec-
ommends anticoagulation for a minimum of 3months for all
patients with DVT or PE irrespective of the underlying cause
(33). According to the ACCP guidelines anticoagulation should
be stopped after 3months in patients with a transient risk fac-
tor like surgery, trauma, immobilization, pregnancy, or female
hormone intake (34–37). The ACCP guidelines do not address
treatment with DOAC. In the Amplify study investigating Apix-
aban for the treatment of acute VTE patients with a transient
risk factor and “less than 6months of anticoagulant treatment
planned” were excluded (13). Therefore, the anticoagulation with
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Apixaban might not be recommendable for such patients because
of a lack of data. The other large clinical studies investigating
dabigatran, rivaroxaban, and edoxaban for the treatment of VTE
included patients with a transient risk factor for VTE, but the
optimal duration of anticoagulation was not specifically inves-
tigated for this particular patient group and therefore remains
to be elucidated. Whether recommendations for the duration of
anticoagulation will be influenced by the designs of the DOAC
trials still has to be awaited until the publication of the revised
guidelines.
Infinite anticoagulation should be considered in patients with
a spontaneous proximal DVT (from the vena poplitea upwards)
or PE, as they are at high risk of recurrence. The benefits of
anticoagulation have to be weighed against the risk of bleeding
and personal preferences. Therefore, an individualized treatment
approach should be pursued. In line with this approach, a risk
assessment model was published for the identification of patients
with unprovoked VTE in whom a only limited duration of antico-
agulation can be considered as relatively safe (38).
Heritable thrombophilic defects are found in at least one-third
of patients with acute VTE (39). Screening for heritable throm-
bophilia may therefore be promising and has been advocated.
However, in unselected patients with a first episode of VTE it
has been shown that testing for heritable thrombophilia does not
allow the prediction of VTE recurrence (40–45). Moreover, it has
to be considered that VTE is a multifactorial disease and that a
negative finding from thrombophilia testing could result in a false
sense of safety in a patient or even the treating physician, as a
third of patients with recurrent VTE do not have a thrombophilic
defect (46). We conclude that thrombophilia screening should
not be performed on a routine basis. In specific cases, such as
younger patients with VTE (including oral contraceptive users),
investigation of lupus anticoagulants, antiphospholipid antibod-
ies, antithrombin III deficiency, and protein C and protein S
deficiency might be performed on a case-by-case basis.
Treatment of VTE in Specific Patient
Groups
Cancer Patients
The presence of malignancy is a strong and independent risk
factor for the occurrence of VTE (47). The reported incidence
rates of VTE in cancer patients vary widely, and strongly depend
on several patient-, treatment-, and cancer-related risk factors
(48). The occurrence of VTE has a dismal impact on the course
of malignancy and adds to the morbidity and mortality of cancer
patients (49).
The treatment of VTE is more challenging in cancer patients
than in the non-cancer population, as cancer patients are more
likely to develop recurrent VTE during anticoagulation and are
also at increased risk of bleeding (50).
In the 2013 clinical practice guideline update the American
Society of Clinical Oncology (ASCO) recommended anticoagu-
lation with a LMWH for at least six months after VTE in cancer
patients over treatment with a VKA or UFH (51, 52). This recom-
mendation is based on three clinical trials that found superiority of
LMWH over VKA for the prevention of recurrent cancer-related
VTE (53–55). Extended thromboprophylaxis (beyond 6months)
should be considered for patients with active malignancy and
particularly for those with metastatic disease and/or ongoing
chemotherapy. The decision to continue anticoagulation in can-
cer patients should be reassessed in regular intervals considering
the risk of bleeding, quality of life, life expectancy, and patient
preference.
A recent meta-analysis including five randomized controlled
trials found that DOAC are at least comparable to VKA in the
treatment of cancer-related VTE (56). However, interventional
trials comparing the efficacy of DOAC with the standard of care
treatment in cancer patients, i.e., LMWH, are missing so far. A
randomized controlled trial comparing edoxaban to dalteparin in
the treatment of cancer-related VTE is currently starting recruit-
ment (2015, March 6, retrieved from https://clinicaltrials.gov/ct2/
show/NCT02073682?term=edoxabancancer&rank=1).
Pregnant Women
Pregnancy is associated with a two-fold increased risk of devel-
oping VTE (57). Fatal PE is the most common cause of death in
pregnant women in Western countries (58).
Low molecular weight heparins are the treatment of choice
for pregnant women with acute VTE because LMWHs do not
cross the placenta and have already been used in a large number
of patients. According to the current ACCP guidelines weight-
adjusted therapeutic doses of LMWH should be used for the
treatment of VTE during pregnancy and should be continued for
at least 6 weeks following delivery (for a minimum of 3months of
therapy). Twenty-four hours prior to planned delivery discontin-
uation of LMWH is recommended (33).
In contrast, VKAmust not be given to pregnantwomen because
they cross the placenta and intake of a VKA is associated with
embryopathy, particularly in the first trimester (59). DOAC have
not been investigated in pregnant women so far and are therefore
contraindicated (60).
Elderly Patients
In elderly patients the treatment of VTE is challenging. Specific
age-related problems are (amongst others) decreased kidney func-
tion, decreasing body weight, dementia, co-morbidities, and an
increased tendency to fall over. Moreover, elderly patients were
often excluded from clinical trials and therefore some data from
clinical trials might not be applicable to these patients.
Age is an independent risk factor forVTE and a high prevalence
of asymptomatic DVT events was found in patients above 80 years
(61). Also the risk of bleeding complications is increased (60).
However, the rate of fatal PE was 2.5-times higher than the rate
of fatal bleeding in patients below 80 years and 4.5-times higher
in those older than 80 years. Thus, the risk of fatal PE appears to
be more alarming than the bleeding risk.
All treatment regimens for VTE, except for dabigatran, are
similar for elderly and younger patients. Only dabigatran should
be taken at a reduced dose (110mg twice daily) in patients aged
80 years or older. As mentioned, this regimen has not been tested
in clinical trials.
Specific VTE treatment regimens for elderly patients still
remain to be tested in future investigations. Sub-group analyses of
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the large clinical trials that compared DOAC to VKA indicate that
DOAC have a better risk-benefit profile. A meta-analysis com-
paring DOAC to VKA found significantly fewer recurrent VTE
events and a significant reduction in major bleeding in elderly
patients treated with a DOAC (14). In a pooled analysis of the two
EINSTEIN trials significantly less bleeding was found in fragile
patients (defined as age above 75 years or creatinine clearance
below 50mL/min, or bodyweight below 50 kg) taking rivaroxaban
compared to those taking a VKA (62).
Conclusion
Venous thromboembolism is a frequent and potentially life-
threatening event. To date different agents are available for the
effective treatment of acute VTE and the prevention of recur-
rence. DOAC seem to have a more favorable risk-benefit profile
compared to VKA.
Based on individual patient characteristics and laboratory
parameters, patient-specific treatment modalities should be tai-
lored and clinical decision-making should be guided by current
guidelines, risk assessment scores, and data from randomized
controlled trials. Special attention has to be paid to the question
whether extended anticoagulation for secondaryVTE prophylaxis
is indicated.
In specific patient groups like pregnantwomen, cancer patients,
and elderly patients, treatment of VTE is more challenging than
that in the general population. Several additional considerations
have to be taken into account in such patients and treatment
regimens should be determined by experts.
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